Skip to main content

The Globe and Mail

QLT cutting 42 per cent of work force, to take $2-million charge

A vile of Visudyne, a product produced by QLT, in Vancouver November 19, 2004.

Jeff Vinnick/The Globe and Mail

QLT Inc. is cutting 42 per cent of its remaining work force, leaving just 38 employees at the onetime heavyweight in Canada's biotechnology sector.

The Vancouver-based company, which has sold its main product line, said Thursday that its remaining employees after the latest downsizing will be focused on the clinical development of synthetic oral retinoid program.

The plan follows the sale by QLT of Visudyne, its flagship product, to Valeant Pharmaceuticals Inc. for $112.5-million. Visudyne combines an injectable drug and laser light to treat age-related macular degeneration.

Story continues below advertisement

QLT expects to take a $2-million restructuring charge related to the job cuts, said the affected employees will leave during the first half of 2013.

QLT expects to save $3.8-million in annualized expenses once the cuts are fully implemented.

The cuts follow a move by QLT earlier this year to cut 146 of its 214 jobs at the time.

In September, QLT said it planned to buy back up to 3.4 million of its shares over the next year as the first step in a plan to return $100-million to stockholders.

Report an error

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨